As a new wave of biosimilars to treat inflammatory bowel disease— an umbrella term for Crohn disease and ulcerative colitis—enter the US market, a lot of clinical and policy news regarding adalimumab and infliximab biosimilars emerged throughout the month of February.
The Adalimumab Race Continues
On the regulatory side, Sandoz’ citrate-free high-concentration version (HCF) of Hyrimoz, a biosimilar referencing Humira (adalimumab), was granted a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use, bringing the new formulation one step closer to regulatory approval across the European Union.